Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Diplomat Pharmacy, Inc.

Pomerantz LLP is investigating claims on behalf of investors of Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE:  DPLO).  Such investors are advised to contact Robert S. Willoughbyat rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Diplomat and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

On February 22, 2019, Diplomat filed a Form 8-K with the U.S. Securities and Exchange Commission, announcing that it was postponing the release of its Form 10-K for the fiscal year ended December 31, 2018 due to a "recent determination" that it would need to record a non-cash impairment charge upwards of approximately $630 million relating to 2017 acquisitions for its pharmacy benefit management business.  Diplomat also disclosed that it was withdrawing its preliminary 2019 full-year outlook provided in January. 

On this news, Diplomat's stock price fell $7.59 per share, or over 56%, to close at $5.87 per share on February 22, 2019.